As of 2025-07-03, the Intrinsic Value of Briacell Therapeutics Corp (BCT.TO) is -15.87 CAD. This BCT.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.00 CAD, the upside of Briacell Therapeutics Corp is -496.87%.
Based on its market price of 4.00 CAD and our intrinsic valuation, Briacell Therapeutics Corp (BCT.TO) is overvalued by 496.87%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -15.87 - -15.87 | -15.87 | -496.87% |
| P/E | (119.00) - (48.39) | (94.53) | -2463.3% |
| DDM - Stable | (21.35) - (69.01) | (45.18) | -1229.4% |
| DDM - Multi | (4.78) - (12.34) | (6.92) | -273.1% |
| Market Cap (mil) | 24.48 |
| Beta | 1.82 |
| Outstanding shares (mil) | 6.12 |
| Enterprise Value (mil) | 19.47 |
| Market risk premium | 5.10% |
| Cost of Equity | 11.28% |
| Cost of Debt | 5.00% |
| WACC | 7.48% |